Compounds > platinum
Page last updated: 2024-08-22

platinum and Carcinoma, Endometrioid

platinum has been researched along with Carcinoma, Endometrioid in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (50.00)29.6817
2010's1 (25.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Bignotti, E; Bugatti, M; Calza, S; Capoferri, D; Lonardi, S; Odicino, F; Pijnenborg, JMA; Ratti, M; Ravaggi, A; Reijnen, C; Romani, C; Sartori, E; Tognon, G; Zanotti, L1
Cosio, S; Fabrini, MG; Gadducci, A; Laliscia, C; Mazzotti, V; Morganti, R; Paiar, F1
Bamias, A; Diakomanolis, E; Dimopoulos, AM; Markaki, S; Michalas, S; Milingos, S; Papadimitriou, C; Protopapas, A1
Bast, RC; Clark, EA; Cliby, WA; Damokosh, AI; Gershenson, D; Hartmann, LC; Hoersch, S; Iartchouk, N; Kalli, KR; Kaufmann, SH; Lillie, J; Linette, GP; Lu, KH; Ross, JS; Shridhar, V; Smith, DI; Stec, J1

Other Studies

4 other study(ies) available for platinum and Carcinoma, Endometrioid

ArticleYear
L1CAM expression as a predictor of platinum response in high-risk endometrial carcinoma.
    International journal of cancer, 2022, 08-15, Volume: 151, Issue:4

    Topics: Biomarkers, Tumor; Carboplatin; Carcinoma, Endometrioid; Endometrial Neoplasms; Female; Humans; Neoplasm Staging; Neural Cell Adhesion Molecule L1; Platinum; Prognosis

2022
Patterns of Failures and Clinical Outcome of Patients with Early-Stage, High-Risk, Node-Negative Endometrial Cancer Treated with Surgery Followed by Adjuvant Platinum-Based Chemotherapy and Vaginal Brachytherapy.
    Oncology, 2019, Volume: 96, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Brachytherapy; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Combined Modality Therapy; Endometrial Neoplasms; Female; Humans; Hysterectomy; Middle Aged; Neoplasm Staging; Platinum; Retrospective Studies; Survival Analysis; Treatment Failure

2019
The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy.
    European journal of gynaecological oncology, 2004, Volume: 25, Issue:2

    Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Endometrioid; Cathepsin D; Cyclophosphamide; Cystadenocarcinoma, Serous; Female; Humans; Immunohistochemistry; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Platinum; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins c-bcl-2; Receptor, ErbB-2; Survival Analysis; Tumor Suppressor Protein p53

2004
Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Mar-15, Volume: 11, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Paclitaxel; Platinum; Survival Rate

2005